Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960514 · ClinicalTrials.gov registry record
Prospective Decision Impact Trial of KidneyIntelX
A clinical trial of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2, sponsored by Renalytix AI.
- Active
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT04960514 is a study of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2 that is active but no longer recruiting, run by Renalytix AI. The registered enrollment target is 2,000 participants, below the 5,103-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04960514, a study of Diabetic Kidney Disease and Chronic Kidney Disease Stage 2, is active but no longer recruiting, sponsored by Renalytix AI.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST KidneyIntelX
Study Locations (1)
North Carolina
- Atrium Health Wake Forest Baptist - Family Medicine - Piedmont Plaza - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-11-22 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04960514
The ClinicalTrials.gov registry entry for NCT04960514 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,103-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (61% lower). The listed sponsor is Renalytix AI, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.
NCT04960514 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04960514 about?
NCT04960514 is a clinical study titled "Prospective Decision Impact Trial of KidneyIntelX". The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
What is the current status of trial NCT04960514?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2021-11-22. Estimated completion is 2026-12-01.
What conditions does trial NCT04960514 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 1, Chronic Kidney Disease, Stage 3 (Moderate).
What interventions are being tested in trial NCT04960514?
The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04960514?
This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04960514 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Dosimetry of Tc-99m-Tilmanocept
RECRUITING · Phase 1
-
A Long-Term Follow-Up Study of Participants Exposed to REACT
RECRUITING
Explore more on PlainTrial
Diabetic Kidney Disease
All registered trials for this condition
Chronic Kidney Disease Stage 2
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.